T. Sahmoud

发表

PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer

John M. S. Bartlett, Stefan Michiels, Christos Sotiriou, 2013, PloS one.

Radical surgery and postoperative radiotherapy as combined treatment in rectal cancer. Final results of a phase III study of the European Organization for Research and Treatment of Cancer

P. Schlag, J. Bosset, B. Nordlinger, 1997, The British journal of surgery.

Evaluation of Clinical Efficacy of New Medical Treatments in Advanced Colorectal Cancer. Results of a Workshop Organized by the Eortc Gitccg

R. Labianca, D. Kerr, W. Scheithauer, 1998 .

Abstract P6-04-02: Final progression-free survival analysis of BOLERO-2: a phase III trial of everolimus for postmenopausal women with advanced breast cancer

M. Piccart, G. Hortobagyi, J. Baselga, 2012 .

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.

Aaron J Johnson, Fang Jin, Aaron J. Johnson, 2019, Blood.

Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus.

J. Bosset, J. Triboulet, D. Elias, 1997, The New England journal of medicine.

Anastrozole (‘Arimidex’) blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer

J. Dixon, W. Miller, T. Sahmoud, 2002, British Journal of Cancer.

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

E. Thiele, O. Witt, P. J. Vries, 2013, The Lancet.

ffi cacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex ( EXIST-1 ) : a multicentre , randomised , placebo-controlled phase 3 trial

E. Thiele, O. Witt, P. J. Vries, 2012 .

Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

J. Bergh, F. Cardoso, A. Fasolo, 2010, Breast Cancer Research and Treatment.

Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study.

T. Conroy, P. Rougier, D. Wagener, 1996, European journal of cancer.

Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.

M. Piccart, G. Hortobagyi, J. Baselga, 2013, Clinical breast cancer.

Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.

M. Piccart, G. Hortobagyi, J. Baselga, 2013, Journal of the National Cancer Institute.

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2

H. Iwata, Byeong‐Woo Park, H. Mukai, 2013, Breast Cancer.

Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues.

A. Paci, F. André, J. Soria, 2011, European journal of cancer.

PVB chemotherapy in patients with recurrent or advanced dysgerminoma: a Phase II study of the EORTC Gynaecological Cancer Cooperative Group.

S. Pecorelli, G. Favalli, A. van Oosterom, 1998, Clinical oncology (Royal College of Radiologists (Great Britain)).

Chemotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus

J. Bosset, J. Triboulet, D. Elias, 1998 .

Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987). European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group.

H. Rauschecker, W. Stremmel, D. Nitti, 1997, European journal of cancer.

Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.

M. Piccart, G. Hortobagyi, J. Baselga, 2013, European journal of cancer.

P. Neven, M. Piccart, G. Hortobagyi, 2013, Cancer.

Correlation of molecular alterations with efficacy of everolimus in hormone-receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2.

G. Hortobagyi, J. Baselga, M. Campone, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

F. André, M. Campone, J. Soria, 2013, Breast Cancer Research and Treatment.

Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).

C. Isaacs, Bing-he Xu, F. André, 2013 .

Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.

G. Hortobagyi, J. Baselga, H. Rugo, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer

G. Giaccone, P. Postmus, C. Debruyne, 1996 .

Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer. EORTC Lung Cancer Cooperative Group.

G. Giaccone, P. Postmus, C. Debruyne, 1996, Seminars in oncology.

Current and future perspectives on fulvestrant.

W. Gradishar, T. Sahmoud, 2005, Clinical breast cancer.

Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial.

G. Giaccone, G. Scagliotti, P. Postmus, 1996, European journal of cancer.

Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer

M. Hao, M. Korpal, M. Wick, 2022, Molecular cancer therapeutics.

Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study.

R. Audisio, N. Duez, B. Taal, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Radiotherapy and 5-FU after curative resection for the cancer of the pancreas and peri-ampullary region: A phase III trial of the EORTC GITCCG

J. Jeekel, J. Klinkenbijl, T. Sahmoud, 1997 .

Qualitative and chronological assessment of toxicities during treatment with raltitrexed (‘Tomudex’) in 861 patients: implications for patient management

J. Garcia-Vargas, T. Sahmoud, S. Green, 1999 .

Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1.

J. Ajani, Y. Bang, E. Van Cutsem, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.

P. Neven, G. Hortobagyi, J. Baselga, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mesalazine as a maintenance treatment in Crohn's disease: is it the long awaited solution?

T. Sahmoud, J. Mary, 1997, Gut.

Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study.

G. Giaccone, A. Gregor, P. Postmus, 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer

C. Sotiriou, S. Loi, M. Piccart, 2019, PloS one.

The identification of high risk patients with metastatic colorectal cancer

C. Köhne, D. Curran, G. Blijham, 1997 .

Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2.

J. Baselga, H. Rugo, M. Campone, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer

J. Cuzick, A. Howell, J. Forbes, 2003, Cancer.

Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: A multicenter phase II clinical trial.

F. André, M. Campone, F. Dalenc, 2010 .

5004 Multicenter phase I clinical trial of daily and weekly everolimus (RAD001) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab

J. Bergh, F. Cardoso, A. Fasolo, 2009 .

Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine

O. De Witte, J. Hildebrand, T. Sahmoud, 1998, Journal of Neuro-Oncology.

Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group.

L. Collette, T. Sahmoud, B. Luboinski, 1996, Journal of the National Cancer Institute.

Author reply

A. Buzdar, J. Bonneterre, B. Thürlimann, 2002 .

PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer

C. Sotiriou, S. Loi, M. Piccart, 2013, PloS one.

S3-7: Everolimus for Postmenopausal Women with Advanced Breast Cancer: Updated Results of the BOLERO-2 Phase III Trial.

M. Piccart, G. Hortobagyi, J. Baselga, 2011 .

Edinburgh Research Explorer PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer

C. Sotiriou, S. Loi, M. Piccart, 2018 .

Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer.

R. Labianca, M. Buyse, P. Rougier, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Teniposide for brain metastases of small-cell lung cancer: a phase II study. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.

G. Giaccone, E. Smit, P. Postmus, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease

J. Belaiche, R. Modigliani, É. Lerebours, 1996, European journal of gastroenterology & hepatology.

Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study.

L. Collette, J. De Grève, G. Blijham, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

f or R esearch a nd Treatm e nt o f

L. Collette, T. Sahmoud, H. Bleiberg, 1996 .

Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck

A. Graeff, J. Verweij, J. Schornagel, 1996 .

Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.

F. André, M. Campone, J. Soria, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

David Chen, Klemens Budde, K. Budde, 2013, The Lancet.

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.

A. Byars, D. Krueger, T. Sahmoud, 2010, The New England journal of medicine.

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

M. Piccart, G. Hortobagyi, J. Baselga, 2012, The New England journal of medicine.

Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases

D. Lebwohl, Ö. Anak, S. Saletan, 2013, Annals of the New York Academy of Sciences.

Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.

J. Ajani, Y. Bang, E. Van Cutsem, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.

G. Giaccone, P. Therasse, P. Postmus, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group.

J. Verweij, J. Schornagel, F. Cognetti, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group.

G. Giaccone, O. Dalesio, H. Groen, 1997, European journal of cancer.

Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

J. Jeekel, D. González, J. Arnaud, 1999, Annals of surgery.

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

J. Cuzick, J. Forbes, J. Klijn, 2002, The Lancet.

Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2.

G. Hortobagyi, J. Baselga, H. Rugo, 2013 .

Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.

G. Giaccone, A. Ardizzoni, N. van Zandwijk, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: a randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.

G. Giaccone, B. Dautzenberg, N. van Zandwijk, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.

G. Giaccone, G. Scagliotti, P. Postmus, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EDATREXATE VERSUS METHOTREXATE IN HEAD AND NECK SCC 1651

A. Graeff, J. Verweij, J. Armand, 2019 .

p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.

M. J. van de Vijver, C. V. D. van de Velde, A. Mandard, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial.

P. Rougier, D. Nitti, F. Gay, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study.

G. Giaccone, O. Dalesio, A. Gregor, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective EORTC Breast Group study.

M. Piccart, I. Fentiman, R. Paridaens, 1996, European journal of cancer.

Genitourinary group phase II study of chemotherapy in stage T3-4 N0-X M0 transitional cell cancer of the bladder: prognostic factor analysis.

D. Jacqmin, P. Carpentier, T. Sahmoud, 1996, European journal of cancer.

Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer. A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study.

T. Delozier, C. V. D. van de Velde, J. Julien, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identifying patients with a high risk of relapse in quiescent Crohn's disease. The GETAID Group. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.

R. Sylvester, R. Modigliani, É. Lerebours, 1995, Gut.

Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas

D. Áfra, J. Hildebrand, T. Sahmoud, 1994, Neurology.

Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer

J. Dixon, W. Miller, T. Anderson, 2002, British Journal of Cancer.

Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group.

G. Giaccone, M. van Glabbeke, T. Sutedja, 1997, European journal of cancer.

Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.

J. Belaiche, R. Modigliani, A. Adenis, 1994, Gut.

Progression to AIDS in French haemophiliacs: association with HLA-B35.

D. Costagliola, Y. Laurian, Y. Sultan, 1993, AIDS.

Anastrozole is superior to tamoxifen as first‐line therapy in hormone receptor positive advanced breast carcinoma

A. Buzdar, J. Bonneterre, J. Robertson, 2001, Cancer.

Everolimus therapy for angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: Results from EXIST-2.

K. Budde, J. Bissler, M. Fischereder, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial

M. J. van de Vijver, C. V. D. van de Velde, Y. Denoux, 2000, Cancer.

Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer.

L. Collette, T. Conroy, M. Namer, 1997, European journal of cancer.

Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study.

M. Sanson, J. Delattre, T. Sahmoud, 1996, European journal of cancer.

Original Paper Etoposide in Malignant Pleural Mesothelioma: Two Phase II Trials of the EORTC Lung Cancer Cooperative Group

G. Giaccone, T. Sutedja, M. Glabbeke, 1997 .

Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab

F. André, M. Campone, R. O'Regan, 2008 .

Prognostic factors in resectable gastric cancer: Results of EORTC study no. 40813 on FAM adjuvant chemotherapy

R. Labianca, D. Nitti, M. Lise, 1995, Annals of Surgical Oncology.

Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Third Line of TKI Therapy and Beyond Based on Real-World Evidence

D. Wormser, P. Westerweel, T. Sahmoud, 2021, Blood.

Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial

R. Labianca, G. Apolone, H. Rauschecker, 1998, The Lancet.

Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group.

T Sahmoud, G. Giaccone, H. Groen, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of weekly 4'-epidoxorubicin in patients with metastatic adenocarcinoma of the cervix: an EORTC Gynaecological Cancer Cooperative Group study.

J. Vermorken, D. Curran, G. Bolis, 1997, European Journal of Cancer.

Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting

P. Neven, A. Bardia, F. Bidard, 2023, Cancer Research.

Abstract P1-17-10: H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer - A phase II study

M. Korpal, D. Juric, A. Cohen, 2022, Cancer Research.

Phase 1b study of H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor–positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer.

M. Korpal, D. Juric, J. Pipas, 2021 .

Abstract PS12-23: Development of H3B-6545, a first-in-class oral selective ER covalent antagonist (SERCA), for the treatment of ERaWTand ERaMUTbreast cancer

M. Hao, M. Warmuth, M. Korpal, 2021 .

Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets).

G. Hortobagyi, J. Baselga, H. Rugo, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BOLERO-1: A randomized, phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2+), locally advanced or metastatic breast cancer (BC).

M. Buyse, F. André, H. Burris, 2012 .

3LBA Everolimus Added to Exemestane Reduced Bone Markers and Disease Progression in Bone in Postmenopausal Women with Advanced Breast Cancer: Updated Results From the BOLERO-2 Trial

M. Piccart, G. Hortobagyi, J. Baselga, 2012 .

42O_PRASSESSMENT OF GENETIC ALTERATIONS IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER FROM THE BOLERO-2 TRIAL BY NEXT-GENERATION SEQUENCING

M. Piccart, G. Hortobagyi, J. Baselga, 2013 .

P. Neven, M. Piccart, G. Hortobagyi, 2013, Current medical research and opinion.

Maintenance with everolimus (RAD001) and trastuzumab (T) after discontinuation of chemotherapy in patients (pts) with heavily pretreated HER2-positive metastatic breast cancer (MBC): Pooled data of extension cohorts of phase Ib/II studies.

F. André, A. Fasolo, L. Gianni, 2010 .

436 Trastuzumab- (H) and everolimus- (RAD001) containing regimens are safe and active when reintroduced in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) pre-treated with lapatinib

F. André, M. Campone, L. Gianni, 2010 .

Maintenance With Everolimus (RAD001) and Trastuzumab After Discontinuation of Chemotherapy in Heavily Pretreated HER-2+Metastatic Breast Cancer Patients: Pooled Data of Extension Cohorts of Phase Ib/II Studies

F. André, A. Fasolo, L. Gianni, 2010 .

Multicenter phase I clinical trial of daily and weekly RAD001 in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab

J. Bergh, F. Cardoso, A. Fasolo, 2008 .

A novel Bayesian dose-escalation phase Ib design investigating safety of combination of RAD001 with chemotherapy plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab

D. Lebwohl, T. Sahmoud, L. Vittori, 2008 .

H3B-8800-G0001-101: A first in human phase I study of a splicing modulator in patients with advanced myeloid malignancies.

M. Warmuth, P. Greenberg, M. Maris, 2017 .

Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group.

B. Taal, C. Lips, T. Sahmoud, 1995, British Journal of Cancer.

Clinical management and resolution of stomatitis in BOLERO-2.

G. Hortobagyi, J. Baselga, H. Rugo, 2013 .

546 Advanced gastric cancer: Comparison of FAMTX (5FU, adriamycine, methotrexate) versus elf (etroposide, 5 FU, leucovorin) versus FUP (infusional 5 FU + cisplatin). Results from an eortc trial of the GITCCG and the arbeitsgemeinschaft für innere onkologie (AIO)

P. Rougier, D. Curran, E. Cutsem, 1995 .

Radical surgery and postoperative radiotherapy as combined treatment in rectal cancer. Final results of a phase III study of the European Organization for Research and Treatment of Cancer

P. Schlag, J. Bosset, B. Nordlinger, 1997, The British journal of surgery.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2.

G. Hortobagyi, J. Baselga, H. Rugo, 2013 .

Multicenter phase I clinical trial of daily and weekly RAD001 (everolimus) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab.

J. Bergh, F. Cardoso, A. Fasolo, 2009 .

RAD001 (everolimus) in combination with weekly paclitaxel and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab: a multicenter phase I clinical trial.

F. André, M. Campone, M. Naughton, 2009 .

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.

Aaron J. Johnson, L. Pease, N. Kay, 2019, Blood.

Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases

D. Lebwohl, Ö. Anak, S. Saletan, 2013, Annals of the New York Academy of Sciences.

Everolimus for subependymal giant-cell astrocytomas (SEGAs) in tuberous sclerosis (TS).

A. Byars, D. Krueger, T. Sahmoud, 2010 .

Phase II study of weekly 4'-epidoxorubicin in patients with metastatic adenocarcinoma of the cervix: an EORTC Gynaecological Cancer Cooperative Group study.

J. Vermorken, T. Sahmoud, G. Bolis, 1997, European journal of cancer.

Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues.

A. Paci, F. André, J. Soria, 2011, European journal of cancer.